MASER Engineering, the technologically-leading failure and reliability testing center in Europe, and Eurofins Scientific, an international, renowned laboratory group, have entered into an
agreement whereby Eurofins Scientific will acquire the shares of MASER Engineering BV. Current executive management will also participate via a minority shareholding.

MASER and Eurofins share a similar philosophy and complement each other perfectly.Together the two companies have big ambitions to grow the European market specifically in the semiconductor and electronic systems industry. The new ownership will also open up additional opportunities for MASER in the international market, particularly within the Eurofins Materials & Engineering Sciences Business line.

“We are very pleased that, a strong partner has been found who is technically innovative, sustainable and growth-oriented,” explain Hans Kemper and Kees Revenberg, founders and former owners of MASER Engineering. The Dutch operations of MASER will remain in place to continue to serve customers with the best service. MASER’s trademarks of flexibility, delivery reliability and consistent responsiveness to customer needs will be further strengthened. The existing customer and supplier relationships will be continued and intensified.

Thijs Kempers, CEO of MASER, will ensure a smooth continuation of MASER after the acquisition and will continue in his role as CEO. “I am committed to creating continuity for both our customers and our employees and to opening up positive development opportunities for MASER’s employees. Our expansion plans are in progress and I am very confident about MASER’s future.”

About MASER Engineering BV

MASER Engineering was founded in Enschede in 1993 and is an accredited independent engineering testing center with a broad and in-depth range of services. The company is a leader in the fields of reliability testing and failure analysis. The company headquarters are in the ‘Knowledge campus Twente’ (kennispark Twente) in Enschede with a total of 56 employees.

About Eurofins Scientific

With annual sales of over 5 billion euros, 55,000 employees and a network of over 900 independent companies in 50 countries, Eurofins Scientific is a leading international laboratory group, with a unique range of analytical and service capabilities for the pharmaceutical, food, environmental and consumer goods industries. As an accredited and internationally recognized testing laboratory network, Eurofins performs independent testing of technical equipment and components. It also provides conformity assessment solutions for national, European and international market access.

Source: MASER Engineering

Funds played a key role in positioning LUMICKS for future success  

Amsterdam, the Netherlands — May 18, 2021 — LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announces that it has made the decision to return the COVID-related relief funding it received in both the Netherlands and the United States. During 2020, LUMICKS received a total of $1.7 million from the Dutch NOW subsidy and $163,830 from the US Payroll Protection Program.

Olivier Heyning, LUMICKS’s CEO, said: “The decision to voluntarily return the relief funds that we received both in the Netherlands and the US reflects LUMICKS’ values and our desire to create a fairer and better society. We received these funds when we experienced a challenging trading environment due to academic labs cutting back their investment and activities because of the pandemic. We are fortunate that the strong global interest in life science research has placed LUMICKS in a position of robust recovery. This progress and the growing customer interest in our cutting-edge technologies, such as z-Movi® Cell Avidity Analyzer for use in immunology, has allowed LUMICKS to raise further substantial funding from an international syndicate of specialized life sciences investors recently. I would like to thank both the Dutch and US governments for their prompt action in making this critical funding available and to highlight how important it has been in providing us with short term continuity, allowing LUMICKS to stay focused on building the long-term opportunity.”


LUMICKS is a leading life science tools company that develops equipment for Dynamic Single-Molecule and Cell Avidity analysis, two rapidly emerging areas in biology research and immuno-oncology. Built upon innovative technologies, such as optical tweezers (Nobel Prize for Physics 2018) and STED super-resolution (Nobel Prize for Chemistry 2014), LUMICKS tools facilitate the understanding of life to the smallest detail.

LUMICKS tools allow researchers to build the crucial and yet unfinished bridge between structure and function at both a molecular and a cellular level. This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms. LUMICKS’ groundbreaking C-Trap® Optical Tweezers – Fluorescence & Label-free Microscopy, allows scientists for the first time to analyze complex biological processes in real-time. Similarly, z-Movi® Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells. The company was founded in 2014 as an academic spin-off from the research group of Prof. Gijs Wuite, Prof. Erwin Peterman, and Prof. Iddo Heller at the Vrije Universiteit Amsterdam. For more information, visit the company’s website at

Source article: LUMICKS

Today Surfix celebrates its 10th birthday! Surfix was founded as a spin-off from Wageningen University. Recently, the company has been making big steps towards maturity.
Wageningen, The Netherlands, April 1st, 2021

Ten years ago, the founders of Surfix recognized that control of surface properties is a key requirement for successful application of micro- and nanotechnology. And more importantly, they also saw the business opportunity this represented.

Han Zuilhof, founder of Surfix and professor of Organic Chemistry at Wageningen University, said: ”During 15 years of research in my lab we published a number of patents on chemical surface modification. Starting a company seemed like the best way to get something out of them, and I already knew the best person to do this: my former PhD Student Luc Scheres. With Lionix and Aquamarijn we found investors who were not only in it for the money, but also wanted to contribute in other ways. With this combination of conceptual innovation, high-energy drive and sound business experience, we were good to go!”

Surfix started as a provider of R&D services in the field of nanocoatings. In the past decade, Surfix has been growing steadily, developing custom nanocoatings in a wide range of projects for customers of all sorts and sizes. Gradually, a focus on nanocoatings for biosensors and microfluidic devices arose. In this process, Surfix also strengthened and expanded its technology base by developing several new proprietary nanocoating processes.

The next major milestone for Surfix was its acquisition by Dutch companies Lionix International and Qurin Diagnostics in 2019, followed by an additional investment from PhotonDelta in 2020. Surfix is now focusing on developing and marketing a diagnostic platform based on a photonic biochip.

CEO Maarten Buijs said: “Surfix started by developing nanocoating processes, then moved to nanocoating-enhanced components, and is now making the next step to integrate these components in a product. During the last year we have focused on becoming a diagnostics company. All signs are there that Surfix’s unique capabilities in photonic biosensing will enable wide-scale deployment of point-of-need diagnostics in a variety of areas. The initial target areas are early cancer diagnosis, covid-19 detection, and detection of pathogens in water for aquaculture”.

CTO and founder Luc Scheres said: “I am very happy and grateful to celebrate Surfix’s tenth birthday today! We would not have reached this milestone without the hard work of our staff, the loyal trust of our customers and suppliers, and the loving support of our family and close friends. We have come a long way, and I am looking forward to many more exciting developments at Surfix in the years to come!”

Contact for more information or visit

About Surfix

Surfix was founded as a spin-off from the laboratory of Organic Chemistry of Wageningen University & Research in 2011, and was acquired by Dutch companies Qurin Diagnostics and Lionix International in 2019. Surfix received financial support by public private partnership PhotonDelta in 2020 to further grow its photonics business.
Follow us on LinkedIn, Vimeo, Twitter or for more information visit
All trademarks used herein are the property of their respective owners.